デフォルト表紙
市場調査レポート
商品コード
1020435

バーチャル臨床試験の世界市場:成長、動向、COVID-19の影響、予測(2021年~2026年)

Virtual Clinical Trials Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021 - 2026)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 125 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.03円
バーチャル臨床試験の世界市場:成長、動向、COVID-19の影響、予測(2021年~2026年)
出版日: 2021年07月01日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 125 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

バーチャル臨床試験の市場規模は、予測期間中に5.9%のCAGRで成長すると予想されています。

COVID-19のパンデミックにより、世界の大部分で人口移動と輸送システムが停止し、多くの臨床試験患者が試験サイトに参加できなくなり、主任研究者(PI)やその他の臨床スタッフが自宅に限定されました。したがって、試験の遅延とキャンセルが急増しました。Bristol Myers Squibb Co., Pfizer Inc., Merck & Co., Eli-Lilly & Co.は、今後数週間、新しい試験の開始を中止し、既存の研究への採用を一時停止することを発表した増加する企業のリストのに含まれています。2020年4月に発表された Continuum Clinical分析レポートによると、調査対象の臨床試験場所の約30%が、新しい試験研究への患者の登録と、現在登録されている患者の研究スケジュールの順調な維持の両方に大きな影響を与えると予想されます。議会予算局が発表した報告によると、2020年4月に、約30の製薬企業またはバイオテクノロジー企業が試験の中断を報告しました。ここで、仮想試験が製薬企業やバイオテクノロジー企業によって開発された遠隔医療およびデジタル技術と連携して、臨床試験の中断を減らします。

バーチャル臨床試験市場は、研究開発活動におけるヘルスケアセクターの成長のデジタル化の進展と遠隔医療の採用によって推進されています。たとえば、2020年2月、Johnson&Johnsonは、Apple Watchと新しいiPhoneアプリが心不整脈を検出することで脳卒中のリスクを軽減できるかどうかを確認するために、Heartline仮想試験デザイン研究を開始しました。バーチャル臨床試験は、従来の臨床試験よりも採用率が高く、コンプライアンスが高く、中退率が低く、迅速に実施されます。

さらに、ウェブベースの臨床試験の開始、臨床調査企業、バイオテクノロジー企業、製薬企業間の協力、政府による支援イニシアチブなどの技術の進歩が市場を後押しすることが期待されています。たとえば、2020年11月、Parexelは臨床試験センター(CTC)と協力しました。このコラボレーションにより、初期段階の臨床試験を実施するための調査能力が向上します。また、パンデミック時の需要の高まりと初期段階の臨床試験の継続をサポートします。同様に、2020年10月、オラクルはFHI Clinicalと協力して臨床試験の効率を改善し、治療薬の市場投入を早めました。

さらに、心臓病、感染症、神経疾患などの慢性疾患に苦しむ人々の増加、および高齢者人口の増加は、仮想臨床市場の成長を推進する要因の一部です。たとえば、米国疾病予防管理センター(2021)によると、米国では、平均して10人中6人が慢性疾患に苦しんでおり、10人中4人が2つ以上の疾患に苦しんでおり、国の主要な死因となっています。WHOによると、2020年には、慢性疾患が全世界の死亡のほぼ4分の3を占め、虚血性心疾患(IHD)による死亡の71%、脳卒中による死亡の75%、および糖尿病による死亡の70%が発展途上国で発生するとしています。疾病負担の増大に伴い、新薬開発の需要拡大が見込まれます。これはさらに、ヘルスケア業界の技術開発を促進し、それによって市場の成長を促進すると予想されます。

ただし、大量の収集データ、規制当局への信頼性の証明と管理、技術の失敗、データの正確性は、世界のバーチャル臨床試験市場の成長を妨げると予想される課題の一部です。

当レポートではバーチャル臨床試験の世界市場を調査し、市場の概要、市場の成長要因および阻害要因の分析、市場機会、COVID-19の影響、研究計画法・適応症・地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場の推進力
    • ヘルスケアセクターにおけるデジタル化の進展
    • バーチャル臨床試験における技術的進歩
    • 慢性疾患の有病率
  • 市場の抑制要因
    • バーチャル臨床試験に関連する課題
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • 研究計画法別
    • 観察
    • 介入
    • 拡張アクセス
  • 適応症別
    • 循環器疾患
    • 腫瘍学
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東とアフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Clinical Ink Inc.
    • Laboratory Corporation of America Holdings(Covance, Inc.)
    • ICON Plc.
    • IQVIA Inc.
    • LEO Innovation Lab.
    • Medable Inc.
    • Dassault Systemes SE(Medidata Solutions, Inc.)
    • Medpace Holdings Inc.
    • Oracle Corporation
    • Parexel International Corporation
    • Signant Health

第7章 市場機会と動向

目次
Product Code: 72142

The virtual clinical trials market studied was anticipated to grow with a CAGR of 5.9 % during the forecast period.

The COVID-19 pandemic has shut down population movements and transport systems across large parts of the world, preventing many clinical trial patients from attending trial sites and restricting principal investigators (PIs) and other clinical staff to their homes. Hence the flurry of trial delays and cancellations. Bristol Myers Squibb Co., Pfizer Inc., Merck & Co., Eli-Lilly & Co. are among the growing list of companies to have announced a stop to new trial starts, and pauses to recruitment into existing studies, for the next several weeks. According to Continuum Clinical analysis reports published in April 2020, around 30% of the surveyed clinical trial locations are expected to have a significant impact on both enrolling patients for new trial studies and keeping patients who are currently enrolled on track with their study schedules. According to report published by Congressional Budget Office, in April 2020, approximately 30 pharmaceutical or biotech companies had reported a trial disruption. This is where the virtual trial comes into play with telemedicine and digital technologies developed by pharmaceutical and biotech companies to reduce the clinical trials disruption.

The virtual clinical trials market is driven by the growing digitization in the healthcare sector growth in R&D activities and the adoption of telehealth. For example, in February 2020, Johnson & Johnson launched the Heartline virtual trial design study to see if the Apple Watch and new iPhone app could reduce the risk of stroke by detecting cardiac arrhythmia. Virtual clinical trials have higher recruitment rates, better compliance, lower drop-out rates, and are conducted faster than traditional clinical trials.

Moreover, advancements in technology such as the launch of web-based clinical trials, collaborations between clinical research companies, biotechnology companies and pharmaceutical, and support initiatives from governments are expected to boost the market. For example, In November 2020, Parexel came into collaboration with the Clinical Trial Center (CTC). This collaboration will increase the research capacity of delivering early Phase clinical trials. It will also support the rising demand and continuation of early phase clinical studying during the pandemic. Similarly. In October 2020, Oracle collaborated with FHI Clinical for improving the efficiency of the clinical trial and helped in getting therapies to market faster

Additionally, the increasing occurrence of people suffering from chronic diseases such as heart diseases, infectious diseases, neurological diseases, and the rising geriatric population are some of the factors that propel the growth virtual clinical market. For instance, according to the Center for Disease Control and Prevention (2021), in the United States, on an average 6 out of 10 people are suffering from a chronic disease, and 4 out of 10 people are suffering from two or more, resulting in the leading cause of death in the country. According to WHO, In 2020, chronic diseases accounted for almost three-quarters of all deaths worldwide, and that 71% of deaths due to ischaemic heart disease (IHD), 75% of deaths due to stroke, and 70% of deaths due to diabetes will occur in developing countries. With increasing burden of diseases, it is expected to increase the demand for the development of new drugs. This is further anticipated to fuel the technological development in the healthcare industry and thereby, augment the market growth.

However, a greater amount of collection data, prove and manage reliability to the regulators, technology failure, data accuracy, are some of the challenges that are anticipated to hamper the growth of the global virtual clinical trials market.

Key Market Trends

The Oncology Segment is Expected to Occupy a Significant Share of the Market Over the Forecasts Period

The oncology segment is expected to dominate the market over the forecasts period due to increasing government initiatives for cancer awareness, rising in the prevalence of cancer, increasing R&D activities on the development of cancer drugs, therefore, increases the number of oncological trials. According to Globocan 2020 fact sheet, an estimated 19,292,789 cancer cases were diagnosed with 9,958130 death due to cancer.

The worldwide cancer burden is rising, worldwide. Virtual clinical trials minimize the cancer patient's risk (risk of Immunosuppression, travel burden, therapeutic diversity, and regulatory complexity) and by decreasing time spent on face-to-face trial visits. To keep patients safe, oncology clinical trial investigators and sponsors have quickly incorporated virtual and remote trials. In October 2019, Georgetown University Medical Center used cloud-based virtual interconnected computing techniques for deducting the time in accessing cancer patients' profiles. which indicates that the number of cases virtually assessed augmented from 46 to 622 as compared to the conventional assessments from 3 to 14 cases from 2014-2017.

According to National Clinical Trials, in April 2020 there are around 8306 clinical trials on oncology across the various phases of development. As the number of clinical trials increased there are higher chances of increasing the demand for virtual clinical trials. Thus above-mentioned factors are expected to drive the segment over the forecasts period

North America is Currently Dominating the Virtual Clinical Trials Market and is Expected to Continue in the Forecasts Period

Geographically, North America accounts for one of the largest revenue holders in the global virtual clinical trials market due to the presence of major companies that manufacture pharmaceuticals coupled with rising government and companies that focus on investment in the development of new medicines. In November 2019, Janssen pharmaceutical subsidiary of Johnson & Johnson in collaboration with the PRA Health Sciences, launched a digital clinical trial set-up CHIEF-HF a completely decentralized, indication-seeking, mobile clinical study. The company aims to utilize wearable devices and smart technology to efficiently gather and analyze evidence for assessing the effectiveness of Canagliflozin in the populace with heart failure with the presence or absence of type 2 diabetes.

Moreover, the region is expected to continue its dominance over the forecasts period. This can be attributed to increasing R&D in this region, increasing the adoption of new technologies in clinical research, and government support. Furthermore, market players are also using digital technologies to meet client needs. For instance, In year 2020, Parexel performed more than 100 decentralized trials including hybrid and virtual/decentralized approaches. However, due to an increase in cancer cases and other chronic diseases, the virtual clinical trials market is likely to boost significantly throughout the forecast period.

Competitive Landscape

The virtual clinical trials market is highly competitive and consists of several major players. The players operating in this market are operating on different competitive factors such as experience in the pharmaceutical, experience in clinical trials, and investment in technology. The strategies adopt by the market participants are Partnerships, Collaborations, agreement, product launch, and product expansion. The players namely Clinical Ink inc., IQVIA Holdings, Inc., ICON PLC, Laboratory Corporation of America Holdings (Covance, Inc.), LEO Innovation Lab., Dassault Systemes SE (Medidata Solutions, Inc.), Oracle Corporation, Parexel International Corporation, Medable, Inc. and Signant Health.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Digitization in Healthcare Sector
    • 4.2.2 Technological Advancements in Virtual Clinical Trials
    • 4.2.3 Prevalence of Chronic Disease
  • 4.3 Market Restraints
    • 4.3.1 Challenges Associated with the Virtual Clinical Trials
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Study Design
    • 5.1.1 Observational
    • 5.1.2 Intervensional
    • 5.1.3 Expanded Access
  • 5.2 By Indication Type
    • 5.2.1 Cardiovascular Disease
    • 5.2.2 Oncology
    • 5.2.3 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Clinical Ink Inc.
    • 6.1.2 Laboratory Corporation of America Holdings (Covance, Inc.)
    • 6.1.3 ICON Plc.
    • 6.1.4 IQVIA Inc.
    • 6.1.5 LEO Innovation Lab.
    • 6.1.6 Medable Inc.
    • 6.1.7 Dassault Systemes SE (Medidata Solutions, Inc.)
    • 6.1.8 Medpace Holdings Inc.
    • 6.1.9 Oracle Corporation
    • 6.1.10 Parexel International Corporation
    • 6.1.11 Signant Health

7 MARKET OPPORTUNITIES AND FUTURE TRENDS